| HoLEP在长期口服抗凝剂前列腺增生病人中的应用 |
| |
| 引用本文： | 马继慈,徐鹏程,许全超,李增稳,陈德钢,伍宏亮. HoLEP在长期口服抗凝剂前列腺增生病人中的应用[J]. 蚌埠医学院学报, 2022, 47(9): 1222-1224. DOI: 10.13898/j.cnki.issn.1000-2200.2022.09.017 |
| |
| 作者姓名： | 马继慈 徐鹏程 许全超 李增稳 陈德钢 伍宏亮 |
| |
| 作者单位： | 1.安徽医科大学附属六安医院(六安市人民医院) 泌尿外科，安徽 六安 2370052.蚌埠医学院第一附属医院 泌尿外科，安徽 蚌埠 233004 |
| |
| 摘 要： | 目的分析经尿道钬激光前列腺剜除术(HoLEP)治疗长期口服抗凝剂前列腺增生病人的有效性及安全性。方法回顾性分析205例前列腺增生病人临床资料，将100例口服抗凝剂病人作为观察组，105例未口服抗凝剂病人作为对照组。比较2组病人手术时间、血红蛋白下降量、冲洗时间及留置导尿时间。术后随访3个月，比较2组术后最大尿流率、残余尿量、国际前列腺症状评分、生活质量评分。结果所有病人均顺利完成手术，无术中术后输血、包膜穿孔、电切综合征等并发症。观察组手术时间长于对照组(P < 0.05)，2组术后血红蛋白下降量、冲洗时间和留置导尿管时间差异均无统计学意义(P>0.05)。2组术后3个月最大尿流率、残余尿量、国际前列腺症状评分、生活质量评分差异均无统计学意义(P>0.05)。结论HoLEP治疗长期口服抗凝剂前列腺增生病人安全有效，值得临床推广。
|
| 关 键 词： | 前列腺增生 钬激光 抗凝剂 |
| 收稿时间： | 2021-06-22 |
Clinical study on the application of HoLEP in prostatic hyperplasia patients with long-term oral anticoagulants |
| |
| Affiliation: | 1.Department of Urology, Lu′an Hospital Affiliated to Anhui Medical University, Lu′an People′s Hospital, Lu′an Anhui 2370052.Department of Urology, The First Affiliated Hospital of Bengbu Medical College, Bengbu Anhui 233004, China |
| |
| Abstract: | ObjectiveTo analyze the efficacy and safety of transurethral holmium laser enucleation of the prostate (HoLEP) in the treatment of prostatic hyperplasia patients with long-term oral anticoagulants.MethodsThe clinical data of 205 patients with prostatic hyperplasia were retrospectively analyzed.One hundred patients with oral anticoagulants were set as the observation group, and 105 patients without oral anticoagulants were set as the control group.The operation time, hemoglobin decrease amount, washing time and indwelling catheter time were compared between the two groups.The patients were followed up for 3 months, and the maximum urine flow rate, residual urine volume, international prostate symptom score, and quality of life score after operation were compared between the two groups.ResultsThe operation in all the patients was successfully completed, and there were no complications such as intraoperative and postoperative blood transfusion, capsule perforation, and electrotomy syndrome.The operation time in the observation group was longer than that in the control group (P < 0.05), and there were no significant differences in the hemoglobin decrease amount, washing time and indwelling catheter time between the two groups after operation (P>0.05).There were no significant differences in the maximum urine flow rate, residual urine volume, international prostate symptom score and quality of life score between the two groups at 3 months after operation(P>0.05).ConclusionsHoLEP is safe and effective in the treatment of prostatic hyperplasia patients with long-term oral anticoagulants, and is worthy of clinical promotion. |
| |
| Keywords: | |
|
| 点击此处可从《蚌埠医学院学报》浏览原始摘要信息 |
|
点击此处可从《蚌埠医学院学报》下载免费的PDF全文 |
|
